A drug-resistant fungus capable of causing severe and sometimes life-threatening infections has now been reported in 26 states, although health officials say most healthy people do not face a significant risk of becoming seriously ill.
More than 3,000 clinical cases of Candida auris, commonly shortened to C. auris, have been reported across the United States during 2026. Provisional data from the Centers for Disease Control and Prevention showed 3,437 cases as of July 25.
Candida auris is a type of yeast that can cause illnesses ranging from infections affecting the skin or wounds to dangerous infections in the bloodstream. The symptoms can differ depending on where the infection develops and how severe it becomes.
There is no single set of symptoms associated exclusively with the fungus. Patients with an infection may experience signs commonly connected to other bacterial or fungal illnesses, including fever and chills.
One reason C. auris has become a serious public-health concern is its ability to resist antifungal medications. Some strains do not respond to one or more commonly used treatments, making infections difficult and, in uncommon situations, potentially impossible to treat with existing drugs.
Most infections can still be treated with a class of antifungal medications known as echinocandins. However, the CDC says some strains have developed resistance to all three major classes of antifungal drugs.
The fungus is primarily found in hospitals, nursing homes and other health care environments where patients may already be seriously ill. It can spread rapidly among people receiving complicated or prolonged medical care.
Patients with severe underlying medical conditions face the greatest risk of developing a serious infection. Those who rely on invasive medical equipment are also particularly vulnerable because the devices can provide pathways for the fungus to enter the body.
Examples include breathing tubes, feeding tubes, intravenous catheters and urinary catheters.
Most people without serious medical problems or those risk factors are unlikely to become sick from C. auris. Health care employees, visitors and family members generally do not need to be routinely screened simply because they entered a facility where the fungus was detected.
However, people can carry C. auris on their skin or elsewhere on their bodies without experiencing symptoms. This condition is known as colonization.
A colonized person may never become ill but can still spread the fungus to nearby objects, surfaces or other patients. Infected patients and people carrying the fungus without symptoms can both contribute to its transmission.
Candida auris can remain on a person’s skin or other areas of the body for an extended period. A patient may continue spreading it even when no symptoms are present.
The fungus can also survive for long periods on objects and surfaces frequently touched inside medical facilities. Those surfaces may include bedrails, doorknobs, blood-pressure cuffs and other equipment used during patient care.
Not every cleaning product is effective against C. auris, which can make outbreaks particularly difficult to control. Health care facilities must use disinfectants specifically shown to work against the fungus.
As of July 25, cases had been reported in Arizona, Colorado, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maryland, Michigan, Mississippi, Nevada, New Jersey, New Mexico, North Carolina, North Dakota, Ohio, Pennsylvania, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin and West Virginia.
The number of reported infections has risen dramatically since the fungus was first identified in the United States in 2016.
The CDC recorded only 48 clinical cases nationwide during 2016. By 2024, the annual total had climbed to 6,304 clinical cases.
Although infections continue to increase and the fungus has appeared in new geographic areas, federal health officials say the rate of growth has slowed since 2022. The number of cases and the speed at which they are increasing also vary considerably from one state to another.
The 2026 figures are considered provisional. Health care providers and laboratories report infections to state and local public-health agencies, which then voluntarily submit case notifications to the CDC.
Those totals may rise or fall as health departments review information and reconcile reports. Final annual case counts may therefore differ from the numbers published in weekly surveillance updates.
Early detection is considered one of the most important methods for controlling an outbreak. Because patients can carry the fungus without showing symptoms, health care facilities may screen people by collecting and testing swabs from their skin.
Facilities can also reduce transmission by separating infected or colonized patients from vulnerable individuals whenever possible. Medical workers caring for affected patients may be required to wear gloves and gowns.
Frequent hand cleaning with alcohol-based sanitizer is another important precaution. Patient rooms and equipment must also be disinfected regularly with cleaning agents that are effective against C. auris.
The CDC advises patients who previously tested positive for the fungus to tell medical professionals about that history before receiving care at another facility.
For most members of the general public, the nationwide increase does not mean ordinary daily activities now carry a high risk of infection. The greatest concern remains among severely ill patients, people receiving complex medical treatment and those using invasive devices in health care settings.
Source: Arizona’s Family



